Dupuis M et al. |
Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. |
1999 |
Vaccine |
pmid:10519932
|
Boyce TG et al. |
Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. |
2000 |
Vaccine |
pmid:10930676
|
O'Hagan DT et al. |
Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. |
2000 |
Vaccine |
pmid:10699327
|
Meier S et al. |
Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. |
2011 |
Vaccine |
pmid:21419775
|
Parretta E et al. |
Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. |
2011 |
Vaccine |
pmid:21406267
|
Morel S et al. |
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. |
2011 |
Vaccine |
pmid:21256188
|
Keitel W et al. |
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. |
2010 |
Vaccine |
pmid:19835829
|
Vesikari T et al. |
MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. |
2009 |
Vaccine |
pmid:19840662
|
Tsai T et al. |
Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis. |
2010 |
Vaccine |
pmid:19969117
|
Della Cioppa G et al. |
Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. |
2011 |
Vaccine |
pmid:21906647
|
Fox CB et al. |
Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. |
2011 |
Vaccine |
pmid:21906648
|
Singh M et al. |
A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. |
2006 |
Vaccine |
pmid:16300864
|
Del Giudice G et al. |
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. |
2006 |
Vaccine |
pmid:16464520
|
Precioso AR et al. |
A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. |
2011 |
Vaccine |
pmid:21945258
|
Pariani E et al. |
Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. |
2011 |
Vaccine |
pmid:21974995
|
Andrews NJ et al. |
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. |
2011 |
Vaccine |
pmid:21875635
|
Fukase H et al. |
Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. |
2012 |
Vaccine |
pmid:22472791
|
Hatz C et al. |
A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. |
2012 |
Vaccine |
pmid:22446638
|
Van Buynder PG et al. |
The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. |
2013 |
Vaccine |
pmid:23933368
|
Vinay TN et al. |
Inactivated vaccine against viral hemorrhagic septicemia (VHS) emulsified with squalene and aluminum hydroxide adjuvant provides long term protection in olive flounder (Paralichthys olivaceus). |
2013 |
Vaccine |
pmid:23896420
|